Author | Rod McNeil; Reviewed by Dr David S. Boyer, Prof. Ramin Tadayoni, Dr Jeffrey S. Heier and Dr Paul Hahn


Brolucizumab for neovascular AMD: Safety guidance and clinician perspectives

Although the majority of patients experience benefit with brolucizumab for the treatment of nAMD without severe adverse events, the risk of retinal vasculitis and/or retinal vascular occlusion needs to be balanced with potential benefits.